Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH is an Fmoc-protected β-substituted alanine bearing a benzo[1,3]dioxin-derived aromatic substituent at the β-position, providing a chiral amino acid framework with a stereogenic center at the alanine α-carbon. The molecule contains an Fmoc carbamate on the amino group, a free carboxylic acid for C-terminal peptide coupling, and a rigid, polycyclic benzo[1,3]dioxin aromatic system that can influence conformational preferences and hydrophobic/aromatic interactions in peptide scaffolds. The benzo[1,3]dioxin motif includes acetal-like oxygen atoms that can participate in chemical transformations under appropriate conditions while remaining stable under standard peptide synthesis conditions. The combination of a protected amine, a reactive acid handle, and a stereodefined β-aryl substituent makes the compound a targeted chiral intermediate for peptide building block preparation and downstream derivatization chemistry.

1. Protected Amino Acid Synthesis

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH is suited for protected amino acid chemistry where orthogonal reactivity between the Fmoc carbamate and the free carboxylic acid is required for controlled peptide assembly. The Fmoc group enables base-mediated deprotection while preserving the benzo[1,3]dioxin aromatic substituent, and the β-substituted stereocenter supports incorporation of a defined side-chain topology into peptide sequences. The carboxylic acid functionality supports activation-based coupling strategies to form amide bonds with incoming amino acid residues. The resulting protected amino acid intermediate can be used to generate sequence-defined peptides and peptide analogs that contain a rigid aromatic β-substituent for structure-function studies and synthetic methodology development.

2. Peptide Synthesis

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH is applicable to solid-phase peptide synthesis and related peptide coupling workflows that rely on Fmoc-compatible building blocks. The Fmoc-protected amine supports stepwise chain elongation, while the free carboxylic acid enables formation of the peptide bond at the alanine α-carboxylate position during coupling. The β-benzo[1,3]dioxin substituent introduces steric bulk and aromatic character adjacent to the backbone, which can modulate local conformations, backbone torsion preferences, and side-chain orientation in the growing peptide. The stereodefined β-substitution allows incorporation of chiral, nontrivial amino acid analogs for generating peptides with tailored physicochemical profiles and for probing how constrained aromatic motifs affect peptide folding and binding.

3. Peptidomimetics And SAR Studies

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH serves as a chiral fragment for peptidomimetic construction and structure-activity relationship studies that require systematic variation of backbone substitution patterns. The benzo[1,3]dioxin aromatic system can be used as a rigid hydrophobic/aromatic pharmacophore element, while the β-position substitution provides a handle for exploring how proximity of aromatic bulk to the peptide backbone influences recognition. The Fmoc-protected amino acid format supports rapid generation of analog series by swapping this β-substituted residue into otherwise consistent peptide scaffolds. The downstream peptide analogs derived from this building block can be applied in SAR mapping, conformational analysis, and molecular design workflows aimed at correlating stereochemistry and side-chain placement with observed binding or functional readouts in biochemical assays.

4. Chemical Biology Labeling

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH can be employed in chemical biology research where amino acid-derived handles are needed for biomolecule modification and probe construction. The Fmoc-protected amino acid architecture supports incorporation into peptide-based ligands, which can then be used to generate conjugatable biomolecule scaffolds after peptide assembly and deprotection. The benzo[1,3]dioxin motif, with its oxygen-containing aromatic framework, may serve as a stable aromatic reporter or as a scaffold for further functionalization to introduce additional reactive groups for conjugation strategies. The resulting labeled or derivatized peptide constructs can be used to study molecular recognition, localization, or interaction networks using amino acid chemistry-compatible probe designs.

5. Process Chemistry Intermediate Preparation

Fmoc-beta-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH is relevant to process chemistry and specialty chemical production as a defined chiral intermediate for manufacturing peptide building blocks with controlled stereochemistry. The presence of an Fmoc-protected amine and a free carboxylic acid allows manufacturing routes to be designed around predictable protection/deprotection and coupling compatibility, reducing cross-reactivity during intermediate handling. The rigid benzo[1,3]dioxin substituent provides a chemically stable aromatic motif that can persist through typical peptide synthesis steps, supporting downstream conversion into larger peptide intermediates. The compound can therefore function as a reproducible feedstock for producing customized peptide reagents, research-grade peptidomimetics, and industrially manufactured libraries of Fmoc-based amino acid derivatives.

1. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

3. Multifunctional peptide-oligonucleotide conjugate promoted sensitive electrochemical biosensing of cardiac troponin I

4. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes